Despite a global slowdown in elective procedures, Stryker increased fourth-quarter sales by 3.2% to about $4.3 billion, though it fell short of Wall Street estimates. The quarter is slightly down from third-quarter results, which executives attributed to the procedure drop off, but the quarter was a significant improvement over the 24.3% sales decline taken in the second quarter.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,